High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity

DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metabol., 7, 11, 10.1016/j.cmet.2007.10.002 Tennant, 2010, Targeting metabolic transformation for cancer therapy, Nat. Rev. Canc., 10, 267, 10.1038/nrc2817 Tennant, 2009, Metabolic transformation in cancer, Carcinogenesis, 30, 1269, 10.1093/carcin/bgp070 Zhang, 2015, Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents, Drug Discov. Today, 20, 1112, 10.1016/j.drudis.2015.03.012 Yu, 2008, Structures of the human pyruvate dehydrogenase complex cores: a highly conserved catalytic center with flexible N-terminal domains, Structure, 16, 104, 10.1016/j.str.2007.10.024 Patel, 2009, Interaction of E1 and E3 components with the core proteins of the human pyruvate dehydrogenase complex, J. Mol. Catal. B Enzym., 61, 2, 10.1016/j.molcatb.2009.05.001 Patel, 2006, Regulation of the pyruvate dehydrogenase complex, Biochem. Soc. Trans., 34, 217, 10.1042/BST0340217 Wigfield, 2008, PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer, Br. J. Canc., 98, 1975, 10.1038/sj.bjc.6604356 Hur, 2013, Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target, Int. J. Oncol., 42, 44, 10.3892/ijo.2012.1687 Sun, 2017, Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel, Oncotarget, 8, 52642, 10.18632/oncotarget.16991 Lu, 2011, Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer, Am. J. Pathol., 179, 1405, 10.1016/j.ajpath.2011.05.050 Trinidad, 2017, Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells, Oncogene, 36, 6164, 10.1038/onc.2017.224 Mayers, 2003, AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa/fa) Zucker rats, Biochem. Soc. Trans., 31, 1165, 10.1042/bst0311165 Hiromasa, 2008, Specific ion influences on self-association of pyruvate dehydrogenase kinase isoform 2 (PDHK2), binding of PDHK2 to the L2 lipoyl domain, and effects of the lipoyl group-binding site inhibitor, Nov3r, Biochemistry, 47, 2312, 10.1021/bi7014772 Kato, 2007, Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol, Structure, 15, 992, 10.1016/j.str.2007.07.001 Knoechel, 2006, Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands, Biochemistry, 45, 402, 10.1021/bi051402s Moore, 2014, VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells, Oncotarget, 5, 12862, 10.18632/oncotarget.2656 Meng, 2014, Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90, J. Med. Chem., 57, 9832, 10.1021/jm5010144 Roe, 1999, Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin, J. Med. Chem., 42, 260, 10.1021/jm980403y Sun, 2015, JX06 Selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification, Cancer Res., 75, 4923, 10.1158/0008-5472.CAN-15-1023 Liu, 2017, Development of the first generation of disulfide-based subtype-selective and potent covalent pyruvate dehydrogenase kinase 1 (PDK1) inhibitors, J. Med. Chem., 60, 2227, 10.1021/acs.jmedchem.6b01245 Bonnet, 2007, A Mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth, Cancer Cell, 11, 37, 10.1016/j.ccr.2006.10.020 Zhang, 2016, Unexpected discovery of dichloroacetate derived adenosine triphosphate competitors targeting pyruvate dehydrogenase kinase to inhibit cancer proliferation, J. Med. Chem., 59, 3562, 10.1021/acs.jmedchem.5b01828 Xu, 2018, Rational design of mitochondria-targeted pyruvate dehydrogenase kinase 1 inhibitors with improved selectivity and antiproliferative activity, Eur. J. Med. Chem., 155, 275, 10.1016/j.ejmech.2018.06.012 Jackson, 1998, Heterologously expressed inner lipoyl domain of dihydrolipoyl acetyltransferase inhibits ATP-dependent inactivation of pyruvate dehydrogenase complex, Biochem. J., 334, 703, 10.1042/bj3340703 Qin, 2016, Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth, Oncotarget, 7, 1395, 10.18632/oncotarget.6366 Yee, 1997, In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth, Pharm. Res. (N. Y.), 14, 763, 10.1023/A:1012102522787 Brough, 2017, Application of off-rate screening in the identification of novel pan-isoform inhibitors of pyruvate dehydrogenase kinase, J. Med. Chem., 60, 2271, 10.1021/acs.jmedchem.6b01478 Blanchfield, 2003, Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of α-conotoxin MII, J. Med. Chem., 46, 1266, 10.1021/jm020426j Howes, 2006, A fluorescence polarization assay for inhibitors of Hsp90, Anal. Biochem., 350, 202, 10.1016/j.ab.2005.12.023 Espinal, 1995, Inhibition of pyruvate dehydrogenase kinase by halogenated acetophenones, Drug Dev. Res., 35, 130, 10.1002/ddr.430350303